CANF

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Today, 7:05 AMCan-Fite BioPharma gets Australian patent allowance for Namodenoson in advanced metastatic liver and pancreatic cancer

Peers: APRE BCDA BIVI CALC CVM GOVX KAPA KPRX LNAI NEUP

Scroll to Statements

Index	-
Market Cap	7.17M
Enterprise Value	-1.30M
Income	-9.90M
Sales	0.41M
Book/sh	4.27
Cash/sh	3.99
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	5
IPO	Nov 01, 2012

P/E	-
Forward P/E	-
PEG	-
P/S	17.49
P/B	0.79
P/C	0.84
P/FCF	-
EV/EBITDA	-
EV/Sales	-3.17
Quick Ratio	3.46
Current Ratio	3.46
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	No / No

EPS (ttm)	-12.45
EPS next Y	-0.27
EPS next Q	-0.33
EPS this Y	88.61%
EPS next Y	60.29%
EPS next 5Y	-
EPS past 3/5Y	45.54% 45.72%
Sales past 3/5Y	-20.32% -11.88%
EPS Y/Y TTM	66.33%
Sales Y/Y TTM	-
EPS Q/Q	66.85%
Sales Q/Q	-20.25%
Earnings	Mar 26 BMO
EPS/Sales Surpr.	- -

Insider Own	-
Insider Trans	-
Inst Own	6.45%
Inst Trans	0.24%
ROA	-
ROE	-
ROIC	-176.49%
Gross Margin	94.07%
Oper. Margin	-2456.76%
Profit Margin	-2426.65%
SMA20	3.27%
SMA50	2.89%
SMA200	-34.89%
Trades

Shs Outstand	0.23M
Shs Float	-
Short Float	-
Short Ratio	0.17
Short Interest	0.32M
52W High	21.00 -84.05%
52W Low	2.56 30.86%
Volatility	7.55% 12.28%
ATR (14)	0.45
RSI (14)	51.63
Beta	1.10
Rel Volume	9.54
Avg Volume	1.88M
Volume	895,949

Perf Week	-3.74%
Perf Month	17.54%
Perf Quarter	14.73%
Perf Half Y	-19.08%
Perf YTD	-16.25%
Perf Year	-83.74%
Perf 3Y	-94.49%
Perf 5Y	-99.27%
Perf 10Y	-99.95%
Recom	1.00
Target Price	8.00
Prev Close	3.26
Price	3.35
Change	2.76%

Date	Action	Analyst	Rating Change	Price Target Change
May-13-26	Upgrade	D. Boral Capital	Hold → Buy	$7
Aug-11-17	Initiated	Maxim Group	Buy	$7
Oct-19-16	Resumed	ROTH Capital	Buy
Aug-29-16	Resumed	Rodman & Renshaw	Buy	$6
Nov-30-15	Reiterated	H.C. Wainwright	Buy	$4 → $6
Mar-31-15	Reiterated	H.C. Wainwright	Buy	$7 → $3
Mar-30-15	Downgrade	ROTH Capital	Buy → Neutral	$20 → $2.40
Dec-29-14	Reiterated	ROTH Capital	Buy	$28 → $20
Nov-18-14	Initiated	H.C. Wainwright	Buy	$7

Today 07:00AM	Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer (GlobeNewswire)
Jul-06-26 07:00AM	Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027 (GlobeNewswire)
Jul-01-26 07:00AM	Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease (GlobeNewswire) +55.89%
Jun-26-26 07:00AM	Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology (GlobeNewswire) -6.46%
Jun-22-26 07:00AM	Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson (GlobeNewswire)
07:00AM	Loading…
Jun-17-26 07:00AM	Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026 (GlobeNewswire)
Jun-02-26 07:00AM	Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson's RAS Signaling Inhibition Mechanism (GlobeNewswire)
May-18-26 07:00AM	Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis Market (GlobeNewswire)
May-13-26 07:00AM	Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy (GlobeNewswire) +7.37%
Apr-30-26 08:31AM	Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months (GlobeNewswire) +6.69%
Mar-30-26 07:20AM	Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 (GlobeNewswire)
Mar-26-26 09:27AM	Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient (GlobeNewswire)
Mar-17-26 07:47AM	Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance (GlobeNewswire)
Mar-05-26 09:18AM	CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data (Zacks) -23.59%
Mar-04-26 10:25AM	Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds (GlobeNewswire) +20.40%
10:07AM	Loading…
10:07AM	Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study (Benzinga)
07:00AM	Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study (GlobeNewswire)
Feb-17-26 07:00AM	Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson (GlobeNewswire)
Feb-09-26 07:00AM	Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy (GlobeNewswire)
Feb-05-26 07:00AM	Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson (GlobeNewswire) +5.20%
Jan-20-26 07:00AM	Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson (GlobeNewswire)
Dec-26-25 07:00AM	Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction (GlobeNewswire) +18.64%
Dec-23-25 04:46PM	Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change (GlobeNewswire) -25.03%
Dec-16-25 09:19AM	Can-Fite Provides Update on Clinical and Financial Status (GlobeNewswire) +9.06%
Nov-26-25 07:00AM	Can-Fite's Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference (GlobeNewswire)
Nov-24-25 07:00AM	Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference (GlobeNewswire) +11.99%
Nov-20-25 07:00AM	Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil (GlobeNewswire) -6.95%
Nov-18-25 07:00AM	Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson (GlobeNewswire) +5.00%
Sep-15-25 07:00AM	Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson (GlobeNewswire)
Aug-28-25 08:47AM	Can-Fite Reports H1 2025 Financial Results and Clinical Update (GlobeNewswire)
07:04AM	Loading…
Jul-30-25 07:04AM	Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone (GlobeNewswire) -5.26%
Jul-28-25 12:24PM	Can-Fite Announces Up To $15.0 Million Public Offering (GlobeNewswire) -28.43%
07:00AM	Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia (GlobeNewswire)
Jun-16-25 09:00AM	Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston (GlobeNewswire) +6.54%
May-05-25 08:00AM	Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis (GlobeNewswire)
Apr-17-25 08:55AM	Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients (GlobeNewswire)
Apr-14-25 02:28PM	Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares (GlobeNewswire) -17.20%
08:30AM	Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships (GlobeNewswire)
08:00AM	Can-Fite Reports 2024 Financial Results and Clinical Update (GlobeNewswire)
Mar-24-25 09:00AM	Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol (GlobeNewswire)
Mar-20-25 09:45AM	Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market (GlobeNewswire) -7.28%
Mar-19-25 09:00AM	Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson (GlobeNewswire) -19.38%
Mar-18-25 08:30AM	Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient (GlobeNewswire) +22.42%
Mar-03-25 06:00AM	Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits (GlobeNewswire)
Feb-18-25 07:00AM	Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson (GlobeNewswire)
Feb-10-25 07:10AM	Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25 (GlobeNewswire)
Feb-05-25 07:00AM	Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025 (GlobeNewswire) +5.76%
Jan-28-25 10:30AM	Can-Fite BioPharma secures US patent for Namodenoson (Pharmaceutical Technology)
Jan-27-25 07:00AM	US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug (GlobeNewswire)
Jan-09-25 12:00PM	CanFite Biopharma (CANF) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Dec-30-24 07:00AM	Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson (GlobeNewswire)
Dec-09-24 09:55AM	Bears are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now (Zacks)
Dec-04-24 07:00AM	8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite's Namodenoson Drug (GlobeNewswire) -20.10%
Nov-22-24 09:00AM	60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Nov-11-24 07:00AM	Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial (GlobeNewswire)
Nov-05-24 07:28AM	Can-Fite BioPharma Secures Australian Patent for Obesity Drug (TipRanks)
Nov-04-24 07:08AM	Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia (GlobeNewswire)
Oct-18-24 09:06AM	Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson (GlobeNewswire) +6.30%
Oct-09-24 07:00AM	FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer (GlobeNewswire) +15.20%
Oct-07-24 07:00AM	Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on October 29 (GlobeNewswire)
Sep-24-24 07:00AM	Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis (GlobeNewswire)
Sep-16-24 07:00AM	Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health (GlobeNewswire)
Aug-30-24 09:48AM	Is Can-Fite BioPharma Ltd. (CANF) The Best Rated Penny Stock To Buy According to Analysts? (Insider Monkey)
Aug-29-24 08:15AM	Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies (GlobeNewswire)
Aug-09-24 09:00AM	OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Aug-08-24 07:01PM	Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds (GlobeNewswire) +12.50%
Jul-29-24 07:00AM	Can-Fite Provides Namodenoson Patent Update (GlobeNewswire) -13.21%
Jul-17-24 07:00AM	Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8 (GlobeNewswire)
Jul-11-24 07:00AM	Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer (GlobeNewswire)
Jul-01-24 07:00AM	Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson (GlobeNewswire)
Jun-28-24 07:00AM	Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fites Partner Vetbiolix (Business Wire)
Jun-24-24 07:00AM	Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver (Business Wire) +5.32%
Jun-10-24 07:00AM	Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study (Business Wire)
Jun-05-24 07:00AM	Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study (Business Wire)
May-29-24 07:00AM	Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases (Business Wire)
May-27-24 07:00AM	Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024 (Business Wire)
May-23-24 07:00AM	Join Can-Fites Exclusive Live Investor Webinar and Q&A Session on June 6 (Business Wire)
May-13-24 07:00AM	Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study (Business Wire)
May-10-24 09:00AM	Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
06:23AM	Can-Fite receives FDA IND clearance for Phase IIb MASH treatment trial (Clinical Trials Arena)
May-09-24 07:00AM	Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study (Business Wire) +6.03%
May-06-24 07:00AM	Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602 (Business Wire)
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-25-24 07:00AM	Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal (Business Wire)
Apr-15-24 07:00AM	Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH (Business Wire)
Apr-03-24 07:00AM	Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients (Business Wire)
Apr-01-24 07:00AM	Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV (Newsfile)
Mar-28-24 07:00AM	Can-Fite Reports 2023 Financial Results and Clinical Update (Business Wire)
Mar-11-24 07:00AM	Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference (Business Wire)
Feb-28-24 07:00AM	Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada (Business Wire)
Jan-30-24 07:00AM	Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication (Business Wire)
Jan-29-24 07:00AM	Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study (Business Wire) +7.14%
Dec-20-23 07:00AM	The Anti-Obesity Effect of Can-Fites Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies (Business Wire)
Dec-18-23 07:00AM	Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan (Business Wire)
Dec-04-23 07:00AM	Can-Fites Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development (Business Wire)
Nov-30-23 07:00AM	Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update (Business Wire)
Nov-22-23 07:23AM	Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson (Zacks)
Nov-21-23 01:53PM	Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds (GlobeNewswire) +6.73%
07:00AM	Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson (Business Wire)
Nov-01-23 07:00AM	Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track (Business Wire)

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.

FounderDr. Pnina Fishman Ph.D.

CEOMr. Motti Farbstein

Vice President of Business DevelopmentDr. Sari Fishman Ph.D.

M.D.Dr. Stephen A. Harrison FACP

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Can-Fite Biopharma Ltd ADR

Upgrade your Finviz experience